Purpose. We assessed the fast-acting bactericidal activity and substantivity of olanexidine gluconate (OLG) to investigate its remaining bactericidal activity on the skin after rinsing and drying by using an ex vivo Yucatan micropig (YMP) skin model.
INTRODUCTION
Antiseptics are used extensively in hospitals and other healthcare settings and play an important role in the infection control practices used to prevent nosocomial infections. We found that the biguanide compound, olanexidine gluconate [1-(3,4-dichlorobenzyl)À5-octylbiguanide mono-D-gluconate (OLG; development code: OPB-2045G)], has antimicrobial activity against a wide range of bacteria, especially Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) [1, 2] . OLG's mechanism of action has been proposed to work as follows: OLG binds to the cell membrane, disrupts membrane integrity, and exerts its bacteriostatic and bactericidal activities by causing irreversible leakage of intracellular components. At relatively high concentrations, OLG aggregates the cells through the proteindenaturing effect [1] . A 1.5 % OLG formulation has been used clinically for preoperative skin preparation in Japan since 2015 [3] . However, there is little information available on the persistent activity and related chemical characteristics of OLG.
Chlorhexidine gluconate (CHG), also a biguanide compound, is an antiseptic that has been used for a long time, and it shows excellent long-term activity [4] [5] [6] [7] [8] . Alcoholbased formulations containing CHG at concentrations of 0.5 to 2 % showed significantly greater persistent activity compared to that shown by alcohol-based formulations without CHG [6] [7] [8] . These formulations are widely used in clinical settings for various purposes, including hand hygiene and the disinfection of surgical and catheter-insertion sites.
Typically, the efficacy of antiseptics is evaluated using in vitro suspension tests, and not in vivo animal models. However, the persistence of an agent's activity cannot be evaluated by performing in vitro studies. Moreover, an accurate evaluation of the persistence of effects is difficult even in clinical trials as well as in studies performed using in vivo animal models. In vivo animal models pose several challenges related to skin structure and pathogenic bacteria, which are different from those in humans. Thus, an ex vivo model is considered to provide solutions to the several problems associated with the use of animal models in addition to having other advantages, which led us to use the ex vivo skin contamination model in this study [9] [10] [11] [12] .
The Yucatan micropig (YMP) is hairless and the morphological and functional characteristics of its skin are comparable to those of human skin [13, 14] . Furthermore, many reports have described the use of YMP skin for drugpermeability studies [14, 15] . This model affords the following advantages: YMP skin is commercially available and can be kept frozen for a long period of time, thus allowing flexibility in experiment initiation; the skin can be inoculated with various human pathogens under various conditions; and the model allows for an accurate quantitative determination of antimicrobial activity [9] . In this study, we attempted to evaluate the fast-acting bactericidal activity and substantivity (which is the persistence of an agent's antimicrobial effect on the skin after rinsing and drying) [16, 17] of OLG by using an ex vivo skin model.
METHODS

Test substance and antiseptics
Olanedine antiseptic solution 1.5 % (Otsuka Pharmaceutical Factory, Inc., Tokushima, Japan), which contains polyoxyethylene (20) polyoxypropylene (20) glycol as a solubilizing agent in addition to active ingredient, Stericlon W solution 0.5 % (Kenei Pharmaceutical Co. Ltd, Osaka, Japan), Hexizac AL solution 1 % (Yoshida Pharmaceutical Co. Ltd, Tokyo, Japan) and Isodine solution 10 % (Mundipharma K K, Tokyo, Japan) were used as 1.5 % OLG, 0.5 % CHG, 1 % CHG in 83 % ethanol (1 % CHG-AL), and 10 % povidone-iodine (10 % PVP-I), respectively. An aqueous solution containing 1.5 % CHG and 70 % isopropanol containing 2 % CHG (2 % CHG-IPA) were prepared from Hibitane gluconate solution (Sumitomo Dainippon Pharmaceutical Co. Ltd, Osaka, Japan), distilled water (Otsuka Pharmaceutical Factory, Inc.) and 2-propanol (Wako Pure Chemical Industries Ltd, Osaka, Japan).
Bacterial strains and preparation of the test bacterial suspension
The following bacterial strains were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA): Staphylococcus aureus subsp. aureus (ATCC 33591, MRSA), Enterococcus faecalis (ATCC 51575, VRE), Staphylococcus epidermidis (ATCC 12228), Acinetobacter baumannii (ATCC 19606), Corynebacterium minutissimum (ATCC 23348) and Cutibacterium acnes (ATCC 11827, formerly Propionibacterium acnes). The MRSA, E. faecalis, S. epidermidis, A. baumannii and C. minutissimum were grown on soybean-casein digest agar (Nissui Pharmaceutical Co. Ltd, Tokyo, Japan) at 35 C under aerobic conditions, and C. acnes was grown on reinforced clostridial agar (Nihon Pharmaceutical Co. Ltd, Tokyo, Japan) at 35 C under anaerobic conditions. The grown colonies were suspended in distilled water to prepare the test bacterial suspensions of McFarland no. 1 using McFarland standard (bioM erieux SA, Marcy l'Etoile, France).
Pigskin preparation
Commercially available YMP skin sets were purchased from Charles River Laboratories Japan, Inc. (Kanagawa, Japan). Each YMP skin set consisting of 16 sheets (approximately 10 cmÂ10 cm per sheet) was excised from one female YMP (5 months old). The YMP skin sets were stored at À80 C until use. Immediately before use, the sheets were thawed in an incubator maintained at 35 C for 10 min and the subcutaneous fat was removed from all sheets. Then, 1 sheet was cut into 16 pieces (each 2 cmÂ2 cm or 1.5 cmÂ1.5 cm) with a surgical knife, and the resulting skin pieces were disinfected by being soaked in 70 % ethanol for 5 min.
Evaluation of fast-acting bactericidal activity
The ex vivo skin contamination model was established by modifying previously reported methods [9] [10] [11] [12] . Briefly, a YMP skin piece (2 cmÂ2 cm) was uniformly inoculated with 10 µl of the test bacterial suspension through an inoculation loop and air-drying. Then, 20 µl of each antiseptic (1.5 % OLG, 0.5 % CHG, 1 % CHG-AL, or 10 % PVP-I), which was a sufficient quantity to cover the skin piece, was dropped onto the inoculated YMP skin piece and spread using an inoculation loop. After 30 s or 3 min of antiseptic application, the skin piece was recovered in 10 ml of diluting fluid containing a neutralizer [phosphate buffer solution with 0.1 v/v % Triton X-100 in addition to 10 w/v % polysorbate 80, 1.167 w/v % soybean lecithin, 0.5 w/v % sodium thiosulfate hydrate and 1 w/v % Tamol NN8906 (pH 7.8 to 7.9)] [18] to neutralize the bactericidal activity of the antiseptics.
To establish the control, the antiseptic-untreated YMP skin piece was recovered using the same procedure. An aliquot of the diluting fluid recovered from the skin piece was serially diluted using the same neutralizer-containing diluting fluid. The viable bacteria in the serially diluted fluids were counted by the pour plate method using soybean-casein digest agar or reinforced clostridial agar containing 0.1 % lecithin and 0.7 % polysorbate 80. The detection limit of the viable bacterial count was 10 colony-forming units (c.f.u.) per skin piece. Log 10 reduction was calculated as the difference between the viable bacterial count for the control skin piece and the skin piece treated with the antiseptic shown with a log 10 scale. When the determined viable bacterial count was lower than the detection limit, the value was considered to be 10 c.f.u. per skin piece. We confirmed that the neutralizer used in the bacterial count quenched the antimicrobial activity of the test antiseptics effectively and was not toxic to the test bacteria according to ASTM E1054-08 (Standard Test Methods for Evaluation of Inactivators of Antimicrobial Agents) [19] .
Evaluation of substantivity, which is the remaining bactericidal activity on the skin after rinsing and drying A 20 µl aliquot of each antiseptic was dropped onto a YMP skin piece (2 cmÂ2 cm) and spread using an inoculation loop. After 3 min of antiseptic application (1.5 % OLG, 0.5 % CHG, 1 % CHG-AL, 2 % CHG-IPA, or 10 % PVP-I), which was the time required for the drying of the antiseptic, the YMP skin pieces were rinsed with 1 ml of distilled water. Then, they were incubated at 35 C for 4, 6, 8 or 12 h. After incubation, the pieces were uniformly inoculated with 10 µl of the test bacterial suspension using an inoculation loop to estimate persistent bactericidal activity. After 1 min of inoculation, the skin piece was recovered in 10 ml of a neutralizer-containing diluting fluid. To establish the control, an untreated YMP skin piece was subjected to rinsing and incubation and was recovered using the same procedure. The viable bacteria in the diluting fluids were quantified using the above-mentioned methods. Log 10 reduction was calculated from the determined number of viable cells (c.f.u. per skin piece).
Cutaneous distribution of the residual antiseptic agents A 20 µl aliquot of each antiseptic (1.5 % OLG or 1.5 % CHG) was dropped onto a YMP skin piece (1.5 cmÂ1.5 cm) and spread uniformly using an inoculation loop. After 3 min of antiseptic application, the YMP skin pieces were rinsed with 1 ml of distilled water. Immediately after air-drying, or at 4, 8 or 12 h after incubation at 35 C, the layers of the stratum corneum (SC) of the antiseptic-treated skin pieces were removed using 15 or 20 consecutive adhesive tape strips (Standard DSquame Discs, CuDerm Corp., Dallas, TX, USA) [20] . The residual OLG or CHG in each layer of the SC was extracted with methanol, and then the extract was centrifuged to remove debris and subjected to ultrahigh-performance liquid chromatography (UPLC). UPLC was performed using an ACQUITY UPLC system (Waters Corp., Milford, MA, USA) with a YMC-triart C18 column (2.0 mm i.d.Â100 mm long, 1.9 m particle size; YMC Co. Ltd, Kyoto, Japan). The chromatographic conditions for OLG analysis were as follows: eluent, acetonitrile : water : formic acid, 55 : 45 : 0.1; flow rate, 0.3 ml min ; injection volume, 5 µl; and detection, UV at 259 nm. The total amount of residual OLG or CHG in the SC was the sum of the amounts in each SC layer. The lower limit of quantification (LLOQ) of the amount in each SC layer was 0.6 and 0.3 µg for OLG and CHG, respectively. When the detected peak area was less than the LLOQ, the quantified amount was set to be half of the LLOQ.
Statistical analysis
The data were analysed by Tukey's multiple comparison test at the same time point or between each time point. Alpha was set at 0.05, and the SAS 9.2 software program (SAS Institute Japan Ltd, Tokyo, Japan) and EXSUS 7.7 software (CAC Exicare Co., Tokyo, Japan) were used.
RESULTS
Fast-acting bactericidal activity in the ex vivo skin contamination model Before evaluating the substantivity of OLG, the fast-acting bactericidal activity of 1.5 % OLG, 0.5 % CHG, 1 % CHG- Bactericidal activity is expressed in log 10 reductions after 30 s or 3 min of antiseptic application in Table 1 . With regard to the log 10 reduction at 30 s of exposure against S. aureus ATCC 33591 (MRSA) and vancomycin-resistant E. faecalis ATCC 51575, the value for 1.5 % OLG was higher than that for 0.5 % CHG and 10 % PVP-I, but did not differ from that for 1 % CHG-AL. The log 10 reduction at 30 s of exposure against S. epidermidis ATCC 12228 for 1.5 % OLG was higher than that for 0.5 % CHG, but did not differ from that for 1 % CHG-AL and 10 % PVP-I. On the other hand, the log 10 reductions of 1.5 % OLG against A. baumannii ATCC 19606, C. minutissimum ATCC 23348 and C. acnes ATCC 11827 did not differ from those of other antiseptics at both exposure times. Therefore, 1.5 % OLG had a bactericidal activity that was similar to or stronger than that of 0.5 % CHG, 10 % PVP-I, or alcohol-based formulations in the ex vivo skin contamination model. The remaining bactericidal activity after rinsing (substantivity) To evaluate substantivity, the YMP skin piece first had 20 µl of the test antiseptics (1.5 % OLG, 0.5 % CHG, 1 % CHG-AL, 2 % CHG-IPA, or 10 % PVP-I) applied. After 3 min of antiseptic application, the skin piece was rinsed with 1 ml of distilled water, which was sufficient to wash the skin surface. Thereafter, the skin piece was incubated at 35 C for 4, 6, 8 or 12 h, and the test bacteria were inoculated on the skin surface. The mean inoculum doses of MRSA ATCC 33591, S. epidermidis ATCC 12228 and vancomycin-resistant E. faecalis ATCC 51575 were 2 to 3Â10 7 , 0.5 to 8Â10 6 and 2 to 3Â10 7 c.f.u. per skin piece, respectively. The viable bacteria remaining at 1 min of exposure were counted in order to measure the quantity of antiseptic molecules retaining bactericidal activity.
When substantivity was evaluated using MRSA ATCC 33591, the log 10 reductions for 1.5 % OLG were higher than those for 0.5 % CHG, 1 % CHG-AL, 2 % CHG-IPA and 10 % PVP-I at all incubation times (Fig. 1a) . When S. epidermidis ATCC 12228 and vancomycin-resistant E. faecalis ATCC 51575 were used, the log 10 reductions for 1.5 % OLG were also higher than those for other antiseptics at all incubation times (Fig. 1b, c) . The differences of the log 10 reductions for 1.5 % OLG were analysed between each time point by Tukey's multiple comparison test. As a result, the value at 12 h was significantly lower than those at 4 and 8 h against S. epidermidis and those at 4, 6 and 8 h against VRE. These results suggest that the remaining bactericidal activity of 1.5 % OLG decreases at 12 h.
Even though there were slight differences in the remaining bactericidal activity between each incubation time depending on the type of the test bacteria, the substantivity for 1.5 % OLG was high for at least 12 h and was significantly higher than that for the other antiseptics against MRSA, S. epidermidis and VRE. Antiseptic formulations containing CHG at concentrations of up to 2 and 10 % PVP-I showed small residual bactericidal activity after rinsing.
Quantities of residual antiseptic agents in the SC
The evaluation of the remaining bactericidal activity in the ex vivo skin model showed that 1.5 % OLG maintained its bactericidal activity to a high degree after rinsing and drying. In order to determine the factors contributing to the substantivity, the amount of OLG remaining in the SC was quantified using the tape-stripping method [20] . For a comparison, the same concentration of CHG aqueous solution was applied to YMP skin and the amount of CHG in the SC was measured. The total amount of OLG remaining in the SC was higher than that of CHG at all incubation times ( Table 2 ). For both OLG and CHG, the total amount in the SC remained high until 4 h but decreased at 8 h and thereafter ( Table 2 ). The distribution of the antiseptic agents in the SC indicated that the greatest amount was on the surface (i.e. in tape strip no. 1) and that the quantity decreased with an increase in depth at all incubation times (Fig. 2a, b) . The quantity of the antiseptic agents in the SC layers decreased to almost the lower limit of quantification (LLOQ by the 15th tape stripping (no. 15). The amounts of OLG on the surface immediately after and at 4, 8 and 12 h after rinsing were ca. 11, 17, 8 and 8 %, respectively, and the amounts of CHG were ca. 4, 6, 2 and 2 %, respectively, of those in the case where rinsing was not performed (Fig. 2a, b, c) . The residual amounts of OLG were 2.8 to 4.2 times greater than those of CHG, indicating that the degree of washout for OLG was lower than that for CHG at all incubation times. These results indicated that OLG was more likely to remain on the skin as compared to CHG.
DISCUSSION
In addition to being safe, antiseptics are required to have fast-acting and persistent broad-spectrum antibacterial activity. The fast-acting bactericidal activity of 1.5 % OLG, an aqueous formulation, was compared to that of an alcohol-based formulation, 1 % CHG-AL, in an ex vivo YMP skin contamination model (Table 1) . Against specific Gram-positive bacteria such as MRSA and VRE, the activity of 1.5 % OLG was superior to that of 0.5 % CHG and 10 % PVP-I (Table 1) . This result was similar to previously reported results in an in vivo mouse model [2] . On the other hand, the minimal bactericidal concentrations (MBCs) of OLG, CHG and PVP-I against MRSA ATCC 33591 at 30 s exposure were 434, 2500 and 391 g ml
À1
, respectively, as obtained from the in vitro suspension test; the MBC values were 217, 78.1 and 195 µg ml À1 against S. epidermidis ATCC 12228, and they were 54.3, >5000, and 50 000 µg ml À1 against E. faecalis ATCC 51575, respectively [1, 2] . In the ex vivo skin model, 0.5 % (5000 g ml
) CHG was expected to show a strong bactericidal effect against S. epidermidis ATCC 12228 based on the MBC, but its activity was weaker than that of 1.5 % OLG and 10 % PVP-I. Accordingly, the evaluation of bactericidal activity on skin seems to be more important than the in vitro suspension test. We suggest that an ex vivo pigskin model, in which the morphology and functional characters of the skin resemble those of humans, is more suitable for evaluating the Values are represented as the means±SD (n=3).
SC, stratum corneum; OLG, olanexidine gluconate; CHG, chlorhexidine gluconate bactericidal effect on the skin than a test using rodent skin, such as that of a mouse [13, 14] . OLG also had an adequate, fast-acting activity against clinically important drug-resistant bacteria in an ex vivo model.
Next, we examined the residual drug amount in the SC after rinsing and drying to evaluate the remaining antimicrobial effect on the skin, which is defined as 'substantivity' in the WHO and other guidelines [16, 17] . The residual amount of OLG on the SC surface was 2.8 times or more greater than that of CHG (Table 2) . It was not clear why the OLG amount immediately after rinsing was higher than that at 4 h after rinsing, although the amounts of OLG and CHG were reduced at 8 h after rinsing. It was also found that the OLG amount in the first tape strip, i.e. on the skin surface, was the highest and OLG did not penetrate even when the incubation time was extended (Fig. 2a) . The mechanism underlying OLG's disappearance is unknown, but the results of this study are similar to those of a study investigating the permeability of CHG [23] . The ex vivo model in this study uses skin that does not show sudation, which is considered to be a mechanism that is responsible for the disappearance of the antiseptic agents from the skin. We suggest that OLG has a property to remain on the skin surface and exerts bactericidal activity even if the sudation function is retained. Furthermore, the SC functioned as a barrier to restrict the cutaneous absorption of OLG into the dermis and blood and prevent exposure of the whole body to OLG.
The remaining bactericidal activity after rinsing of OLG remained significantly higher than that of 0.5 % CHG, 1 % CHG-AL, 2 % CHG-IPA and 10 % PVP-I for up to 12 h after rinsing (Fig. 1) . This was perhaps due to the fact that the amount of OLG in the SC was greater than that of CHG ( Table 2 ). The residual amount of OLG on the SC surface at all time points from immediately after to 12 h after rinsing was 8 to 17 % as compared to without rinsing. This means that if 1.5 % (15 000 µg ml
) OLG is applied, 1100 to 2500 µg ml À1 of OLG will remain. The residual amount of CHG on the SC surface at all time points from immediately after to 12 h after rinsing was 2 to 6 % as compared to without rinsing. This means that if a 2 % (20 000 µg ml
) CHG formulation is applied, 470 to 1200 µg ml À1 will remain. Considering the MBCs and the residual amount on the SC surface, the substantivity of the 2 % CHG-IPA against MRSA ATCC 33591 and S. epidermidis ATCC 12228 should be stronger, but such results were not obtained in this study. Furthermore, since the bactericidal activity of OLG is less affected by blood [24] , it cannot be inactivated by organic matter in the SC; in contrast, the bactericidal activity of CHG may be inactivated by organic matter [25, 26] . Many studies have reported the persistent activity of CHG after rinsing or in the absence of rinsing [4] [5] [6] [7] [8] . The substantivity of CHG in our study was lower than that reported previously. Our method for evaluating substantivity was a method of determining bactericidal activity, not bacteriostatic activity. The minimal inhibitory concentrations of CHG were 0.5 to 2 g ml À1 against S. aureus, S. epidermidis and E. faecalis (unpublished data); therefore, the substantivity of CHG may be characterized by a bacteriostatic effect. In a study using a cynomolgus monkey model and in a clinical trial involving preoperative skin preparation, the persistent effect of OLG under non-washing conditions was found to be equivalent to that of other antiseptics, including CHG [24, 27] . The high substantivity of OLG observed in this study can be attributed to the high residual amount present on the skin, which could be enough to exert bactericidal activity, and to the fact that bactericidal activity is not easily influenced by organic matter. That is, OLG has favourable substantivity as an antiseptic. The substantivity of OLG is a particuarly suitable characteristic for products that maintain hand hygiene, which might involve frequent hand washing with water, and may also lead to cumulative effects.
Regarding the safety of OLG, 3 cases of adverse reactions were observed in 3 patients out of 52 subjects (5.8 %) in the clinical trial (phase III) which was conducted with patients undergoing laparoscopic gastrointestinal surgery at 16 Japanese hospitals [27] . The adverse reactions were dermatitis at the application site, erythema at the application site and an itching sensation at the application site, all of which were observed in one case in one patient (1.9 %). In this clinical trial, 10 % PVP-I was used as a control drug, and the incidence rate of the adverse reaction to 1.5 % OLG was not higher than that to 10 % PVP-I. Recently, Nagai et al.
reported that contact dermatitis is induced by OLG [28] . It is possible that the high substantivity of OLG may be involved, but details are not known. Currently, post-marketing surveillance for 1.5 % OLG is ongoing, but the incidence rate for adverse reactions seems not to be significantly higher than that for other antiseptics. We think that further investigation of and research on the skin toxicity of OLG are necessary.
In conclusion, OLG showed fast-acting bactericidal activity that was similar to or stronger than that of the other antiseptics. Its remaining bactericidal activity after rinsing was also higher than that of the other antiseptics in our ex vivo skin model. The residual amount of OLG in the SC was 2.8 times or more greater than that of CHG and it maintained its bactericidal activity, unlike CHG. One of the factors responsible for OLG's high substantivity could be the ability of its molecules to remain in the SC and retain bactericidal activity after rinsing and drying. This property of the OLG molecules is favourable for OLG's application as an antiseptic, as it accounts for OLG's persistent and cumulative effects.
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